MOTS-c
Also known as: Mitochondrial Open Reading Frame
A 16-amino-acid peptide encoded inside the mitochondrial genome — the cell's own metabolic stress signal. Animal data on insulin sensitivity is good; human data is small but growing.
Overview
MOTS-c is one of the more interesting peptides on the longevity side of the catalogue, partly because it is endogenous and partly because the mechanism is unusually clean. Cells secrete it under metabolic stress, it talks to the nucleus, and downstream you get improved fat oxidation and insulin signalling. Lee et al. published the foundational work in 2015; since then a small body of human pharmacokinetic and pilot metabolic data has emerged. The honest read: animals get robust benefits from it, humans seem to get something, and "something" is more than most peptides in this category can claim. Levels also fall with age, which is the basis for the longevity framing.
Evidence quality
Lee, Cohen and colleagues published the discovery in Cell Metabolism in 2015 and have continued the work since. Rodent studies show improvements in insulin sensitivity, exercise capacity, and metabolic flexibility. A small number of human pharmacokinetic and pilot metabolic studies exist; one open-label study in older adults reported improvements in glucose tolerance. No completed Phase 2 trials in the public literature yet.
Benefits & timeline
Benefits
- Improves insulin sensitivity in animal models and in early human work — measurable on glucose tolerance testing
- Increases fat oxidation, especially during exercise — pairs well with training
- Restores some markers of mitochondrial function that decline with age (preclinical mostly)
- Anti-inflammatory effects on adipose tissue in rodent obesity models
Timeline
Week 1–2
Mild energy improvement. Hard to separate from the placebo effect of running a new protocol.
Week 3–4
Recovery between training sessions noticeably better in active users. Less common in sedentary users.
Week 6–8
Body-composition shifts emerge if diet and training are dialled in. The peptide does not produce fat loss on its own.
Off-cycle
4 weeks off after 8 weeks on. Re-evaluate before deciding to repeat.
Dosage protocols
Advanced
10 mg
three times weekly
Beginner
5 mg
twice weekly
Standard
10 mg
twice weekly
Titration & adjustment
Start at 5 mg twice weekly for 2 weeks. If energy and recovery improvements are felt, escalate to 10 mg twice weekly. Maximum 10 mg three times weekly. Cycle off for 4 weeks every 8 weeks.
Injection timing
2–3× weekly. Time of day does not matter pharmacologically — pick the times that fit your schedule and stick to them.
Side effects & contraindications
- mildInjection-site reaction, occasional small wheal.
- mildMild fatigue in the first week as glucose handling shifts.
- mildTransient appetite changes — some users report a slight drop in evening hunger.
- moderateNo long-term human safety data beyond small pilots. The compound is endogenous, which is reassuring, but exogenous chronic dosing has not been studied past months.
Contraindications
- Type 1 diabetes or insulin-dependent type 2 — improved insulin sensitivity can drop blood glucose lower than expected; dose adjustments need a clinician
- Pregnancy or breastfeeding
- Active cancer — mitochondrial signalling crosstalks with tumour metabolism in ways that are not yet clinically mapped
- Severe hypoglycaemia history
Reconstitution & injection
A 10 mg vial mixed with 2 ml bacteriostatic water gives 5 mg per ml. A 10 mg dose draws 2 ml, which is more than most insulin syringes will hold in a single injection — split into two 1 ml shots in different sites, or use a larger 3 ml syringe with a small-gauge needle. Subcutaneous, abdomen or thigh, twice weekly. Reconstituted vials hold up at fridge temperature for around 4 weeks.
Open calculator pre-filledStorage after reconstitution
Refrigerate at 2–8 °C after reconstitution. Do not freeze. Light-protected. 28–30 days of stability at fridge temperature in BAC water. Solution should remain clear and colourless.
Common mistakes
Treating it as a fat-loss drug.
Better approach: The mechanism is metabolic, not lipolytic. In sedentary users on a maintenance diet, body composition will not move much. In active users in a slight deficit, it can shift fat mass downward by improving training capacity. The diet and the training do the work; MOTS-c amplifies them.
Pairing it with a low-carb diet expecting an additive effect.
Better approach: Both improve insulin sensitivity through overlapping pathways. The diet alone may be doing most of the lifting, and you may not be able to see the peptide's contribution. If you want to evaluate MOTS-c, hold diet constant during the trial.
Running it indefinitely.
Better approach: The signalling pathway adapts. 8 weeks on, 4 off is a reasonable cycle. Permanent dosing has no human evidence behind it and the endogenous nature of MOTS-c does not exempt it from feedback regulation.
Real-world tips
- Track fasting glucose and ideally HOMA-IR before starting and at week 8. Subjective energy is noisy; lab numbers are not.
- Inject on training days if possible — the synergy with exercise is the most consistently reported effect.
- Rotate injection sites. The 2 ml volume is enough to cause local soreness if you hit the same spot twice in a week.
- Pair with strength training rather than steady-state cardio if your goal is body composition. The metabolic flexibility upside lands hardest on people who already lift.
- Refrigerate. Discard at 4 weeks.
When something else is the better tool
NAD+
Use instead when: You want a broader mitochondrial-coenzyme top-up and are less interested in the insulin-sensitivity arm. NAD+ has its own evidence picture but the use case is more energy and recovery, less glucose handling.
Metformin
Use instead when: You want a cheap, oral, well-studied insulin sensitiser with decades of outcome data. The trade-off is that metformin can blunt training adaptations if dosed around workouts, which MOTS-c does not.
SS-31 (Elamipretide)
Use instead when: Mitochondrial dysfunction is the specific target (fatigue, neuropathy, age-related decline in energy). SS-31 acts on the inner mitochondrial membrane directly, where MOTS-c works upstream through nuclear signalling.
- Is it the same as exercise?
- It activates some of the same pathways exercise does, particularly around AMPK and fat oxidation. It is not a substitute. The benefits show up most clearly in people who are already training.
- Will it lower my fasting glucose?
- Often yes, modestly. If your starting fasting glucose is already in the normal range, the change is small. If you are pre-diabetic, the effect is more visible.
- How is this different from AICAR?
- AICAR is a small-molecule AMPK activator with rodent-heavy data and a doping ban. MOTS-c is an endogenous peptide that signals more broadly — better human evidence, less stigma, longer protocol cadence.
- Can I take it on rest days?
- Yes. The cadence is twice weekly regardless of training schedule. If you train hard and want the synergy, time injections to training days; otherwise pick two fixed days.